<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60464">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02003235</url>
  </required_header>
  <id_info>
    <org_study_id>RV-TMSC-1</org_study_id>
    <nct_id>NCT02003235</nct_id>
  </id_info>
  <brief_title>Assessment of Device for Treatment of Amblyopia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Visior Technologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Visior Technologies Ltd.</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of Reviview™, a dichoptic video display device for
      administrating a novel treatment protocol for Amblyopia (lazy eye) in kids.

      The effect of the treatment will be measured by the change from baseline in Visual acuity
      and in Stereoscopic Vision; and to assess the ease of use of and compliance by the patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in VA in amblyopic eye</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily watching videos using Reviview™, a dichoptic video display device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Daily watching  videos using Reviview™, a dichoptic video display device, for 60 min</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Refractive or Strabismic Amblyopia, with best corrected visual acuity.

        (1) Refractive Amblyopia, visual acuity score  &lt;6:15 (worse then)

          -  or (2) Strabismic Amblyopia, visual acuity score  between 6:15 and 6:30

        Exclusion Criteria:

        Diagnosed with epilepsy, recently treated with occlusion or penalization therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haim Stolovitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chaim Stolovitch, MD</last_name>
    <phone>+972-3-6974361</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gili Lavi, coordinator</last_name>
      <phone>+972-3-6974361</phone>
    </contact>
    <investigator>
      <last_name>Chaim Stolovitch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>December 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amblyopia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
